Insights Into Metformin XR Pharmacotherapy Knowledge Among Community Pharmacists: A Cross-Sectional Study

• Published in: Clinical medicine insights. Endocrinology and diabetes 2023-01, Vol.16, p.11795514231203913-11795514231203913
• Main Authors: Jairoun, Ammar Abdulrahman, Al-Hemyari, Sabaa Saleh, Shahwan, Moyad, Hassan, Nageeb, Zyoud, Sa’ed H, Jaber, Ammar Ali Saleh, Al-Qirim, Tariq
• Format: Article
• Language: English
• Subjects: Antidiabetics; Drug stores; Knowledge; Original Research; Pharmacists
• ISSN: 1179-5514; 1179-5514
• DOI: 10.1177/11795514231203913

Background: There is a little knowledge on the extent to which healthcare providers understand and accept the professional recommendations and appropriate dosing strategy regarding metformin XR. Objectives: To evaluate UAE community pharmacists’ knowledge, attitude, and practices (KAP) concerning metformin XR. Methods: This is a cross-sectional research study conducted amongst licensed community pharmacists. The survey took place via a questionnaire and physical interviews were held. The survey used in this study included questions on demographics and questions on the participants’ attitudes, knowledge and practices concerning metformin XR. The factors influencing KAP regarding metformin XR were examined via simple logistic regression analysis. Results: Threehundred fifty-three (n = 353) participants were recruited in the study. Independent pharmacies constituted 57.5% of this study sample and 42.5% were chain pharmacies. The average knowledge score about metformin XR tablets was 42.5% with a confidence interval (CI) of 95% [37.3%, 47.4]. Better knowledge scores on metformin XR tablets was observed in respondents aged ⩾40 years (OR 2.97, 95% CI 1.63-5.4), having greater than 10 years in terms of experience (OR 2.28; 95% CI 1.25-4.16) and pharmacist graduated from Regional or international universities (OR 2.08; 95% CI 1.34-3.24). About 78% (n = 275) of the participants believed that metformin XR tablets have better efficacy and 63.2% (n = 233) indicated that metformin IR was associated with greater adverse effects. Conclusion: This study demonstrated a distinct gap in knowledge, attitude and practice pertaining to metformin XR among community pharmacists in the UAE. The community pharmacists need to enhance their practice by receiving accurate and reliable data to support their decision-making on the prescribing of metformin XR. The implementation of novel guidelines and evidence dissemination strategies may help bridge this gap.